Crestwood Advisors Group LLC Has $1.34 Million Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Crestwood Advisors Group LLC grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 19.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 14,497 shares of the biopharmaceutical company’s stock after acquiring an additional 2,321 shares during the period. Crestwood Advisors Group LLC’s holdings in Gilead Sciences were worth $1,339,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in the company. HHM Wealth Advisors LLC increased its stake in shares of Gilead Sciences by 118.5% during the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 154 shares during the period. Valued Wealth Advisors LLC grew its holdings in Gilead Sciences by 101.9% in the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 161 shares in the last quarter. YANKCOM Partnership bought a new position in Gilead Sciences during the 4th quarter worth $28,000. Decker Retirement Planning Inc. bought a new position in Gilead Sciences during the 4th quarter worth $29,000. Finally, Crews Bank & Trust acquired a new stake in shares of Gilead Sciences during the fourth quarter worth $31,000. Institutional investors own 83.67% of the company’s stock.

Insider Activity

In other Gilead Sciences news, insider Merdad Parsey sold 164,211 shares of the business’s stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the sale, the insider now directly owns 80,801 shares of the company’s stock, valued at $7,427,227.92. The trade was a 67.02 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Andrew D. Dickinson sold 8,500 shares of the firm’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $91.96, for a total transaction of $781,660.00. Following the transaction, the chief financial officer now directly owns 132,373 shares of the company’s stock, valued at $12,173,021.08. The trade was a 6.03 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 706,212 shares of company stock valued at $67,324,826 over the last quarter. 0.16% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities analysts recently commented on GILD shares. Bank of America restated a “buy” rating and issued a $109.00 price target on shares of Gilead Sciences in a research note on Tuesday, December 10th. Maxim Group lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Friday, November 8th. Robert W. Baird lifted their price target on shares of Gilead Sciences from $80.00 to $95.00 and gave the company a “neutral” rating in a research report on Thursday, November 7th. Barclays increased their price target on Gilead Sciences from $84.00 to $95.00 and gave the stock an “equal weight” rating in a research report on Thursday, November 7th. Finally, Cantor Fitzgerald restated a “neutral” rating and set a $80.00 price objective on shares of Gilead Sciences in a research note on Wednesday, December 11th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $102.08.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $111.03 on Tuesday. The company’s 50 day moving average price is $95.79 and its two-hundred day moving average price is $89.08. The firm has a market capitalization of $138.37 billion, a P/E ratio of 300.08, a P/E/G ratio of 0.71 and a beta of 0.18. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $111.99.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. On average, equities analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Friday, March 14th will be issued a dividend of $0.79 per share. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 annualized dividend and a dividend yield of 2.85%. The ex-dividend date of this dividend is Friday, March 14th. Gilead Sciences’s payout ratio is 854.05%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.